MBX Biosciences, Inc. Common Stock
$61.57
$0.49 (+0.80%)
$59.49Day Range$62.75
Key Statistics
Market Cap
$2.97B
Shares Outstanding
48.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 13, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$61.34
Day High
$62.75
Day Low
$59.49
Volume
1.16M
VWAP
$61.11
Prev Close
$61.08
Transactions
--
Acc. Volume
--
About MBX Biosciences, Inc. Common Stock
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
PHARMACEUTICAL PREPARATIONSSIC 283463 employees11711 N. MERIDIAN STREET, CARMEL, IN, 46032(317) 989-3100IPO Sep 13, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001776111
- Composite FIGI
- BBG00W7W53M5
- Share Class FIGI
- BBG00W7W53N4
- Ticker Root
- MBX
- SIC Code
- 2834
About MBX Biosciences, Inc. Common Stock (MBX) Stock
MBX Biosciences, Inc. Common Stock (MBX) closed the 2026-09-16 session at $61.57, up 0.80% versus the previous close (+0.49). The stock opened at $61.34 and traded between $59.49 and $62.75 during that session. Session trading volume was 1.2M shares. The volume-weighted average price (VWAP) is $61.11.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
MBX Biosciences, Inc. Common Stock has a market capitalization of $2.97 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MBX is listed on the XNAS exchange. The company employs approximately 63 people. MBX Biosciences, Inc. Common Stock is headquartered in CARMEL, IN. The recorded listing date is 2024-09-13.
On this page you can find market MBX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.